These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 27159166)

  • 1. Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study.
    Cosgrove CA; Lacey CJ; Cope AV; Bartolf A; Morris G; Yan C; Baden S; Cole T; Carter D; Brodnicki E; Shen X; Joseph S; DeRosa SC; Peng L; Yu X; Ferrari G; Seaman M; Montefiori DC; Frahm N; Tomaras GD; Stöhr W; McCormack S; Shattock RJ
    PLoS One; 2016; 11(5):e0152038. PubMed ID: 27159166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations.
    Vajdy M; Singh M; Kazzaz J; Soenawan E; Ugozzoli M; Zhou F; Srivastava I; Bin Q; Barnett S; Donnelly J; Luciw P; Adamson L; Montefiori D; O'Hagan DT
    AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1269-81. PubMed ID: 15588349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation.
    Cranage MP; Fraser CA; Cope A; McKay PF; Seaman MS; Cole T; Mahmoud AN; Hall J; Giles E; Voss G; Page M; Almond N; Shattock RJ
    Vaccine; 2011 Feb; 29(7):1421-30. PubMed ID: 21187177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial.
    Joachim A; Bauer A; Joseph S; Geldmacher C; Munseri PJ; Aboud S; Missanga M; Mann P; Wahren B; Ferrari G; Polonis VR; Robb ML; Weber J; Tatoud R; Maboko L; Hoelscher M; Lyamuya EF; Biberfeld G; Sandström E; Kroidl A; Bakari M; Nilsson C; McCormack S
    PLoS One; 2016; 11(5):e0155702. PubMed ID: 27192151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans.
    Baden LR; Liu J; Li H; Johnson JA; Walsh SR; Kleinjan JA; Engelson BA; Peter L; Abbink P; Milner DA; Golden KL; Viani KL; Stachler MD; Chen BJ; Pau MG; Weijtens M; Carey BR; Miller CA; Swann EM; Wolff M; Loblein H; Seaman MS; Dolin R; Barouch DH
    J Infect Dis; 2015 Feb; 211(4):518-28. PubMed ID: 25165165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap.
    Gray GE; Mayer KH; Elizaga ML; Bekker LG; Allen M; Morris L; Montefiori D; De Rosa SC; Sato A; Gu N; Tomaras GD; Tucker T; Barnett SW; Mkhize NN; Shen X; Downing K; Williamson C; Pensiero M; Corey L; Williamson AL
    Clin Vaccine Immunol; 2016 Jun; 23(6):496-506. PubMed ID: 27098021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN Routes.
    McKay PF; King DF; Mann JF; Barinaga G; Carter D; Shattock RJ
    PLoS One; 2016; 11(2):e0148984. PubMed ID: 26862758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.
    Singh S; Yang G; Byrareddy SN; Barry MA; Sastry KJ
    Vaccine; 2014 Dec; 32(51):6934-6940. PubMed ID: 25444819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics of acute and memory mucosal and systemic immune responses against HIV-1 envelope following immunizations through single or combinations of mucosal and systemic routes.
    Srivastava I; Goodsell A; Zhou F; Sun Y; Burke B; Barnett S; Vajdy M
    Vaccine; 2008 May; 26(22):2796-806. PubMed ID: 18440102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine.
    Cheeseman HM; Day S; McFarlane LR; Fleck S; Miller A; Cole T; Sousa-Santos N; Cope A; Cizmeci D; Tolazzi M; Hwekwete E; Hannaman D; Kratochvil S; McKay PF; Chung AW; Kent SJ; Cook A; Scarlatti G; Abraham S; Combadiere B; McCormack S; Lewis DJ; Shattock RJ
    Hum Gene Ther; 2018 Sep; 29(9):1011-1028. PubMed ID: 30027768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
    Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
    AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins.
    Khattar SK; DeVico AL; LaBranche CC; Panda A; Montefiori DC; Samal SK
    J Virol; 2016 Feb; 90(3):1682-6. PubMed ID: 26581986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial.
    Viegas EO; Tembe N; Nilsson C; Meggi B; Maueia C; Augusto O; Stout R; Scarlatti G; Ferrari G; Earl PL; Wahren B; Andersson S; Robb ML; Osman N; Biberfeld G; Jani I; Sandström E
    AIDS Res Hum Retroviruses; 2018 Feb; 34(2):193-205. PubMed ID: 28969431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations.
    Cristillo AD; Ferrari MG; Hudacik L; Lewis B; Galmin L; Bowen B; Thompson D; Petrovsky N; Markham P; Pal R
    J Gen Virol; 2011 Jan; 92(Pt 1):128-40. PubMed ID: 21169215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms.
    Donnelly L; Curran RM; Tregoning JS; McKay PF; Cole T; Morrow RJ; Kett VL; Andrews GP; Woolfson AD; Malcolm RK; Shattock RJ
    Vaccine; 2011 Jun; 29(27):4512-20. PubMed ID: 21514349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
    Perdiguero B; Gómez CE; Cepeda V; Sánchez-Sampedro L; García-Arriaza J; Mejías-Pérez E; Jiménez V; Sánchez C; Sorzano CÓ; Oliveros JC; Delaloye J; Roger T; Calandra T; Asbach B; Wagner R; Kibler KV; Jacobs BL; Pantaleo G; Esteban M
    J Virol; 2015 Jan; 89(2):970-88. PubMed ID: 25355891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and Sequence.
    Nadai Y; Held K; Joseph S; Ahmed MIM; Hoffmann VS; Peterhoff D; Missanga M; Bauer A; Joachim A; Reimer U; Zerweck J; McCormack S; Cope AV; Tatoud R; Shattock RJ; Robb ML; Sandstroem EG; Hoelscher M; Maboko L; Bakari M; Kroidl A; Wagner R; Weber J; Pollakis G; Geldmacher C
    Front Immunol; 2019; 10():717. PubMed ID: 31105688
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.
    Viegas EO; Kroidl A; Munseri PJ; Missanga M; Nilsson C; Tembe N; Bauer A; Joachim A; Joseph S; Mann P; Geldmacher C; Fleck S; Stöhr W; Scarlatti G; Aboud S; Bakari M; Maboko L; Hoelscher M; Wahren B; Robb ML; Weber J; McCormack S; Biberfeld G; Jani IV; Sandström E; Lyamuya E;
    PLoS One; 2018; 13(11):e0206838. PubMed ID: 30496299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.
    Zurawski G; Shen X; Zurawski S; Tomaras GD; Montefiori DC; Roederer M; Ferrari G; Lacabaratz C; Klucar P; Wang Z; Foulds KE; Kao SF; Yu X; Sato A; Yates NL; LaBranche C; Stanfield-Oakley S; Kibler K; Jacobs B; Salazar A; Self S; Fulp W; Gottardo R; Galmin L; Weiss D; Cristillo A; Pantaleo G; Levy Y
    J Virol; 2017 May; 91(9):. PubMed ID: 28202751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of systemic and mucosal immunization with replicating Single cycle Adenoviruses.
    Matchett WE; Anguiano-Zarate SS; Barry MA
    Glob Vaccines Immunol; 2018 Sep; 3(1):. PubMed ID: 30740532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.